Skip to content
The Nexus
DossierENTITY

ARIA-E

Coverage of ARIA-E in the Nexus archive.

Earliest in view: Jul 28 · 10:00 UTCMost recent: Jul 28 · 10:00 UTC
Co-mentioned in this coverage
ProMIS Neurosciencesorganization1Alzheimer’s diseasetopic1Ariatopic1ARIA-Htopic1
Recent coverage
  • HEALTHJul 28 · 10:00 UTCSTAT NEWS
    STAT+: Preliminary trial results suggest a path to a safer Alzheimer’s treatment

    Preliminary clinical trial results for ProMIS Neurosciences' amyloid-targeting Alzheimer’s treatment showed 4.4% ARIA rates, all mild and asymptomatic, with no cases of severe brain swelling (ARIA-E). The drug demonstrated low brain bleeding (ARIA-H) and suggests potential safety advantages over approved treatments.

ARIA-E · Dossier · The Nexus